Trial Profile
An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult and Elderly Population
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Baxter Healthcare Corporation
- 08 Oct 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record